NewsBenzingaGenmab Presents Updated Phase 2 Data For Petosemtamab Plus Pembrolizumab In First-Line PD-L1–Positive Recurrent/Metastatic Head And Neck Cancer, At ESMO Congress 2026 Genmab Presents Updated Phase 2 Data For Petosemtamab Plus Pembrolizumab In First-Line PD-L1–Positive Recurrent/Metastatic Head And Neck Cancer, At ESMO Congress 2026 Benzinga 2026.10.26 11:18 (GMT+0) Open on Benzinga Other news Parker-Hannifin Earnings Preview: What to Expect HUYA Q3 2026 Preview: Game-Related Services And Advertising Take The Wheel (NYSE:HUYA) Goldman Sachs Maintains Buy on Allegion, Raises Price Target to $206 Why Adobe Stock Is the Best ‘Anti-AI’ Play This Earnings Season Goldman Sachs Maintains Neutral on Duolingo, Raises Price Target to $135 What You Need to Know Ahead of Ralph Lauren’s Earnings Release
